Luis Ortega Paz provides his take on DAPA-MI - A registry-based randomized trial of dapagliflozin in patient with acute myocardial infarction without diabetes, which was presented by Stefan James at AHA 2023 in Philadelphia.

In this section you will find all the necessary information regarding our Content disclaimer, Health-related content disclaimer, Link disclaimer and Copyright.

Read the article with input from Goran Stankovic on this free series of modules that have been carefully prepared by a team of experts and are available both live and on replay

A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...

Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.

Who better to recount its history than the inaugural President of the Euro4C Group? Additionally, insights are provided by the Chairman of PCR, the former EAPCI President, and a pivotal member of the editorial team.

Intravascular imaging is a cornerstone of invasive management of coronary disease, requiring specialized training to interpret either IVUS or OCT. AI can facilitate interpretation by non-specialists in real time.

Global burden of Cardiovascular Disease

Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...

Crossing the aortic valve can pose significant challenges, particularly in cases involving a horizontal aorta, bulky asymmetric calcifications, or prior prosthesis implantation in valve-in-valve procedures. While some TAVI devices feature deflectable delivery systems to enhance coaxiality, current self-expanding valves lack this capability. When standard techniques like...

Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.

Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.

It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...

Lars Wallentin and Stefan James received the Andreas Grüntzig Ethica Award during EuroPCR 2025, on behalf of a wider team of cardiovascular registry experts who have contributed in an extraordinary way to the PCR mission. 

Nicola Ryan provides her take on the FULL REVASC trial which was presented at ACC.24 in Atlanta and published Simultaneously in NEJM.

The FULL REVASC trial is a multicentre registry-based randomised control trial comparing FFR-guided complete revascularisation of non-culprit lesions versus culprit lesion PCI alone in patients presenting...

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...